The rPAP patented resuscitation system consist of a a unique valve, novel nasal interface (prongs) and connection hoses. In a large clinical trial rPAP showed significant improvement – with less death and less intubation in comparison to the standard of care. rPAP can be used with most driver units on the market and is today sold by a partner under license.
A newborn infant has to establish breathing to survive. 100% of the extremely premature infants need support and 4-8% of all infants. Prematurity is a major predictor of death and respiratory disease. The devices providing breathing support are essential tools in all units caring for infants. Avoiding intubation is an important key performance indicator in neonatal care.
Market and potential
In EU about 300 000 infants needs respiratory support at birth and of those 40 000 are pre-term where ventilation is standard of care for both resuscitation and stabilization. In US numbers are higher with 380 000 infants born preterm. The use of continuous positive airway pressure (CPAP) is one of the key recommended interventions to reduce morbidity and mortality in preterm infants.
Standard of care today is the T-piece resuscitation system. It is used together with driver systems from all major companies. Even small hospital in Europe have at least five units ready for emergency use. The system has high imposed resistance to breathing and can only be used with a face mask.
rPAP has proven in a lage clinical study to give a significant better outcome in terms of death and intubation vs the T-piece. Read more here
The key features are:
• Lower resistance to breathing
• Only system with nasal interface as an option
• Easy transportation from delivery to intensive care
• Suitable for mother-child/skin-to-skin
• For resuscitation as well as post-ventilation support
• Large multicenter RCT supporting use
Neores is a spinoff from an academic research group at the Karolinska Institute, Sweden. The academic group consists of clinically active MDs with specialization in neonatology, anesthesiology and intensive care. The company is owned and run by Thomas Drevhammar, MD,PhD and Kjell Nilsson, MD, PhD